HNSN Hansen Medical, Inc. (MM)

Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced today that it will release its financial and operating results for the second quarter ended June 30, 2010 after market close on Wednesday, August 4, 2010.

Hansen Medical will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on August 4, 2010 to discuss its results. The call may be accessed by dialing 888-549-7750 (480-629-9867 for international callers) and via the Internet in the Investor Relations section of Hansen Medical's website at www.hansenmedical.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. Following the call, a webcast replay will be available on Hansen Medical's website, and an audio replay will also be available by calling 800-406-7325 (303-590-3030 for international callers) and entering the access code 4333050. The audio replay will be available through August 11, 2010.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company's robotic navigation system enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. Hansen Medical's Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.

Investor Contacts: Peter Osborne 650.404.5800 Email Contact Lasse Glassen Financial Relations Board 213.486.6546 Email Contact Media Contact: Amy Cook 925.552.7893 Email Contact